JO, I just checked out the FDA site and it looks like ERGO will be presenting today:
ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE
DATE AND TIME: May 13, 14, and 15, 8 a.m.
LOCATION: Holiday Inn, Versailles Ballrooms I and II,
8120 Wisconsin Ave., Bethesda, MD.
CONTACT: Kathleen R. Reedy or LaNise S. Giles, Center for Drug
Evaluation and Research, 301-443-5455.
On May 14, the committee
will discuss Ergoset, (bromocryptine mesylate, Ergoscience) as
monotherapy as an adjunct to diet to improve glycemic control in
patients with non-insulin-dependent diabetes mellitus, whose
hyperglycemia cannot be satisfactorily managed with diet alone;
or concomitantly with a sulfonylurea when diet and Ergoset alone
do not result in glycemic control. |
